Is it safe to discontinue opioids, start buprenorphine/naloxone (Suboxone), and taper benzodiazepines simultaneously?

Can You Stop Opiates, Start Suboxone, and Taper Benzos Simultaneously?

No, you should not attempt to discontinue opioids, initiate buprenorphine/naloxone (Suboxone), and taper benzodiazepines all at the same time—this creates compounding risks of withdrawal complications, respiratory depression, and treatment failure.

The Core Problem: Competing Physiologic Stressors

When you layer multiple medication changes simultaneously, you create a dangerous situation where:

• Opioid withdrawal (even with buprenorphine transition) causes anxiety, insomnia, and autonomic instability
• Benzodiazepine tapering independently causes anxiety, potential seizures, and can precipitate delirium tremens
• Buprenorphine initiation requires careful timing to avoid precipitated withdrawal
• The combination significantly increases respiratory depression risk and overdose mortality 1

The Evidence-Based Approach: Sequential Management

Step 1: Stabilize Opioid Use Disorder First

Initiate buprenorphine/naloxone while continuing benzodiazepines at their current dose. The 2022 CDC guidelines emphasize that tapering decisions should be coordinated between prescribers of all respiratory depressants, and benzodiazepines should be tapered gradually due to serious withdrawal risks including seizures, delirium tremens, and rarely death 2.

• Wait until the patient is stable on buprenorphine (typically 2-4 weeks minimum)
• Monitor for adequate opioid withdrawal suppression
• Assess functional improvement and treatment engagement

Critical Warning: Research shows that 24-31% of patients on buprenorphine receive concurrent benzodiazepines, and this combination increases fatal opioid overdose risk nearly 3-fold (adjusted HR = 2.92,95% CI: 2.10-4.06) 3. However, abrupt benzodiazepine discontinuation carries its own severe risks.

Step 2: Only Then Consider Benzodiazepine Tapering

Once buprenorphine treatment is stable, begin extremely gradual benzodiazepine tapering:

• Taper at 10% per month or slower for long-term users 2
• The CDC explicitly states: "Benzodiazepines should be tapered gradually because of risks (anxiety, hallucinations, seizures, delirium tremens, and, rarely, death) of benzodiazepine withdrawal" 2
• Monitor closely for anxiety exacerbation, sleep disturbance, and seizure risk
• Pause or slow the taper if withdrawal symptoms emerge

Why This Sequence Matters

Prioritizing opioid use disorder stabilization saves lives. Recent evidence demonstrates that concurrent benzodiazepine use, while increasing overdose risk, actually decreases buprenorphine discontinuation rates (adjusted HR = 0.87) 3. This creates a clinical paradox: the benzodiazepines pose overdose risk but may improve retention in OUD treatment, which itself is life-saving.

The 2025 review on concurrent benzodiazepine-opioid use explicitly recommends: "prioritizing OUD stabilization, close monitoring and harm reduction, gradual BZD tapering, and integrated psychosocial interventions" 4. This framework recognizes that attempting everything simultaneously undermines the primary goal—preventing return to illicit opioid use and overdose death.

Practical Implementation

During buprenorphine initiation (while continuing benzodiazepines):

• Educate patients about the significantly increased overdose risk with combined use 1
• Provide naloxone and overdose prevention education
• Schedule frequent follow-up (at least monthly per CDC guidelines) 2
• Monitor for sedation, confusion, or respiratory depression
• Consider reducing benzodiazepine dose if excessive sedation occurs, but do not abruptly discontinue

When ready to taper benzodiazepines:

• Ensure buprenorphine dose is optimized and patient is stable
• Use validated anxiety/insomnia scales to track symptoms
• Integrate psychosocial interventions for anxiety management
• Have a plan to pause or reverse the taper if needed

Common Pitfalls to Avoid

1. Attempting simultaneous changes because you're concerned about polypharmacy—this backfires by destabilizing both conditions
2. Abruptly stopping benzodiazepines due to overdose concerns—this can cause seizures and drive patients away from treatment
3. Refusing buprenorphine to patients on benzodiazepines—the mortality benefit of treating OUD outweighs the interaction risk when properly managed 4, 3
4. Inadequate monitoring frequency—monthly minimum contact is essential during any medication changes 2

The Bottom Line

Stabilize the opioid use disorder first with buprenorphine while maintaining the current benzodiazepine regimen, then pursue gradual benzodiazepine tapering only after achieving stability. This sequential approach balances the competing risks and aligns with both CDC opioid prescribing guidelines 2 and emerging evidence on managing concurrent benzodiazepine use in OUD 4. The alternative—attempting everything simultaneously—substantially increases the risk of treatment dropout, return to illicit opioid use, and overdose death.